Compare KRNT & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRNT | OMER |
|---|---|---|
| Founded | 2002 | 1994 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 668.4M | 772.8M |
| IPO Year | 2014 | 2008 |
| Metric | KRNT | OMER |
|---|---|---|
| Price | $16.03 | $13.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $19.75 | ★ $32.50 |
| AVG Volume (30 Days) | 299.3K | ★ 1.2M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | $4.52 | N/A |
| Revenue Next Year | $7.84 | $233.22 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.93 | $2.95 |
| 52 Week High | $23.48 | $17.65 |
| Indicator | KRNT | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 57.54 | 65.64 |
| Support Level | $14.13 | $10.82 |
| Resistance Level | $16.33 | $17.65 |
| Average True Range (ATR) | 0.51 | 0.62 |
| MACD | -0.01 | 0.21 |
| Stochastic Oscillator | 65.71 | 85.27 |
Kornit Digital Ltd develops, designs and markets digital printing solutions for the world-wide printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software and value-added services that allow for large-scale printing of short runs of complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink and other consumables and service including software subscriptions The company geographically operates in U.S., EMEA, Asia Pacific and other countries. It derives maximum revenue from U.S.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.